Qiagen stock reacts to CEO change and modest analyst upside

Published on 09/21/2026 at 17:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Qiagen stock closed at USD 43.37 on September 18, 2026 on the New York Stock Exchange, about 8.4% below its level at the start of 2026. Analysts currently see a consensus price target of USD 43.51, only slightly above the latest close.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen stock (ISIN NL0012169213) closed at USD 43.37 on the New York Stock Exchange on September 18, 2026, down 2.27% from the prior session and about 8.4% below its level at the beginning of 2026. According to BioSpace on September 21, 2026, the company has called an Extraordinary General Meeting for November 6, 2026 to confirm the appointment of new Chief Executive Officer Jonathan M. Pratt to the Managing Board after he took over the role on September 1, 2026.

Leadership change and upcoming meeting

As BioSpace reports on September 21, 2026, Qiagen has scheduled an Extraordinary General Meeting of Shareholders for November 6, 2026 at 2:00 p.m. CET, where shareholders will vote on Jonathan M. Pratt joining the Managing Board alongside long-time Chief Financial Officer Roland Sackers. The same report notes that former Chief Executive Officer Thierry Bernard stepped down from the Managing Board effective September 1, 2026, and shareholders will be asked to discharge him for his service through that date.

The leadership transition underscores Qiagen’s focus on continuity in its diagnostics and life sciences tools business while bringing in a new top executive, which investors will be watching closely as the company moves into its next reporting cycles. For shareholders, the November 6, 2026 Extraordinary General Meeting marks the next key governance date after the September 1, 2026 CEO handover.

Stock performance and analyst expectations

Data cited in a recent overview show that Qiagen stock traded at USD 43.37 on the New York Stock Exchange as of September 18, 2026, representing a daily decline of 2.27% and placing the shares about 8.4% below their level at the start of 2026. The same overview indicates that the consensus analyst price target currently stands at USD 43.51, which is only around 0.3% above the September 18, 2026 closing price of USD 43.37, suggesting limited expected upside in the near term from the prevailing analyst view.

According to a market summary referencing index data, Qiagen’s share price weakness of 0.93% on a recent trading day contrasted with gains in the broader DAX 40 index, underlining that the stock has underperformed some major benchmarks over the course of 2026 so far. For investors, the combination of an 8.4% year-to-date decline and a consensus price target only marginally above the latest close highlights a cautious stance from analysts as the company navigates its CEO transition and prepares for upcoming investor updates.

Qiagen stock near recent levels

Qiagen stock ended the session on September 18, 2026 at USD 43.37 on the New York Stock Exchange, implying a prior close of roughly USD 44.38 based on the 2.27% daily decline, with trading taking place in USD on the company’s primary listing. At this level, the shares remain clearly above their 52-week low but still well below their 52-week high, positioning the stock in the middle part of its recent trading range as of mid-September 2026.